Ropes & Gray advised Verastem Oncology on the deal. Verastem Oncology (Nasdaq: VSTM) announced that the company has entered into a discovery and development collaboration with...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Verastem, while Covington advised the underwriters in the offering. Verastem, Inc. announced its $85 million public offering of common stock and pre-funded warrants....
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Verastem Oncology in the deal. Verastem Oncology announced a collaboration to evaluate Mirati Therapeutics’ investigational KRAS inhibitor drug with Verastem’s investigational inhibitor drug...
You must be a Standard 1 Year member to access this content.
